Ni Qingtao, Pan Chi, Guo Qing, Wang Peng, Yang Yan, Zhang Wei, Dai Shengbin
Department of Oncology, Hospital Affiliated 5 to Nantong University (Taizhou People's Hospital), Taizhou, China.
Department of General Surgery, Hospital Affiliated 5 to Nantong University (Taizhou People's Hospital), Taizhou, China.
Dose Response. 2022 May 19;20(2):15593258221103373. doi: 10.1177/15593258221103373. eCollection 2022 Apr-Jun.
Lung squamous cell cancer (SCC) and accounts for approximately 20%-30% of all lung cancers. Surgery, chemotherapy and radiotherapy are the main treatments for lung SCC patients. A case with lung SCC patient who was treated using iodine 125 seeds (I-125) because the location of the tumor was adjacent to the great vessels. I-125 is an ideal brachytherapy for lung SCC patients with large masses who lost the chance of operation. I-125 is an adjuvant therapy, combined with chemotherapy and molecular targeting therapy might serve to improve the prognosis of lung SCC patients.
肺鳞状细胞癌（SCC）约占所有肺癌的20%-30%。手术、化疗和放疗是肺SCC患者的主要治疗方法。有一例肺SCC患者因肿瘤位置毗邻大血管而采用碘125粒子（I-125）进行治疗。I-125对于失去手术机会的肺SCC大肿块患者是一种理想的近距离放射治疗。I-125是一种辅助治疗方法，与化疗和分子靶向治疗联合应用可能有助于改善肺SCC患者的预后。
